Hummingbird Bioscience Pte Ltd

36 articles about Hummingbird Bioscience Pte Ltd

• Hummingbird Bioscience and Dartmouth's Geisel School of Medicine to Co-Host 3rd Annual Virtual VISTA Symposium on March 27, 2024

  3/13/2024

  Hummingbird Bioscience and Dartmouth's Geisel School of Medicine announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024.

• Hummingbird Bioscience to Present Two Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics at American Association for Cancer Research (AACR) Meeting 2024

  3/5/2024

  Hummingbird Bioscience announced two upcoming poster presentations at the American Association for Cancer Research Meeting 2024 in San Diego, California.

• Hummingbird Bioscience Strengthens Leadership Team with Appointment of Angèle Maki as Chief Business Officer

  12/11/2023

  Hummingbird Bioscience announced the appointment of Angèle Maki, Ph.D., as Chief Business Officer, effective immediately.

• Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

  10/23/2023

  Hummingbird Bioscience announced presentation of positive clinical data for the dose escalation part of the HMBD-001 Phase I/IIa trial at the European Society for Medical Oncology Congress 2023.

• Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)

  10/19/2023

  Hummingbird Bioscience and Endeavor BioMedicines (“Endeavor”), a clinical-stage company targeting the drivers of fibrosis and oncology, today announced that Endeavor has acquired exclusive worldwide rights to Hummingbird Bio’s antibody-drug conjugate (ADC), HMBD-501.

• Hummingbird Diagnostics Announces Publication of miLung Small RNA-Based Blood Test for Early Detection of Lung Cancer in the Journal of Thoracic Oncology

  7/11/2023

  Hummingbird Diagnostics GmbH announced a publication in the Journal of Thoracic Oncology following a poster presentation at the American Society for Clinical Oncology 2023 Annual Meeting on the miLung small RNA blood test for early-stage lung cancer detection.

• Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023

  5/29/2023

  Hummingbird Bioscience announced a Trials in Progress poster presentation for HMBD-002, a unique anti-VISTA antibody, at the American Society of Clinical Oncology Annual Meeting being held 2-6 June, 2023 in Chicago.

• Hummingbird Bioscience and Merck Enter Collaboration to Evaluate HMBD-001 In Squamous Non-Small Cell Lung Carcinoma

  5/15/2023

  Hummingbird Bioscience announced it has entered into a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001 in combination with cetuximab in squamous non-small cell lung carcinoma.

• Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases

  5/8/2023

  Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, announced an upcoming poster presentation at IMMUNOLOGY2023™.

• Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023

  3/15/2023

  Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, announced two upcoming poster presentations at the American Association for Cancer Research Meeting 2023 in Orlando, Florida.

• Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy

  12/6/2022

  Caris Life Sciences and Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced a strategic collaboration to advance clinical development of Hummingbird Bioscience's anti-HER3 therapy, HMBD-001.

• Hummingbird Bioscience to Attend the Credit Suisse 31st Annual Healthcare Conference

  11/1/2022

  Hummingbird Bioscience today announced that Chief Financial Officer Josh House and Chief Development Officer Leah DiMascio will participate in one-on-one investor meetings at the Credit Suisse 31st Annual Global Healthcare Conference on November 7 - 10, 2022 at the Terranea Resort in Rancho Palos Verdes, CA.

• Hummingbird Bioscience Holds Opening Ceremony for Singapore Science Park Office and Research Facilities

  9/23/2022

  Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, announced the official opening of its office and research facilities at the Singapore Science Park.

• Hummingbird Bioscience Chief Scientific Officer Jerome Boyd-Kirkup to Present at the 2nd Annual VISTA Virtual Symposium

  9/19/2022

  Hummingbird Bioscience today announced that Jerome Boyd-Kirkup , Ph.D., Hummingbird Bioscience's Chief Scientific Officer, will present at the 2nd Annual VISTA Symposium on September 23, 2022.

• Hummingbird Diagnostics Announces Publication of Study on the Utility of miRisk, a Blood-based microRNA Analysis, to Predict Overall Survival for Advanced Non-Small Cell Lung Cancer in npj Precision Oncology

  3/31/2022

  Hummingbird Diagnostics GmbH announced the publication of a study in the journal npj Precision Oncology that describes the discovery and validation of miRisk, a first-of-its-kind microRNA biomarker signature that offers the prospect of a blood-based companion diagnostic for immunotherapy in advanced non-small cell lung cancer.

• Hummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers

  2/9/2022

  Hummingbird Bioscience announced the publication of preclinical data for HMBD-002, a novel anti-VISTA antibody therapeutic, in the Journal for ImmunoTherapy of Cancer, a peer-reviewed journal of the Society for Immunotherapy of Cancer.

• Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies

  12/6/2021

  Hummingbird Bioscience and Cancer Research UK announced that the first patient has been dosed in a Phase 1 clinical trial of HMBD-001 for the treatment of patients with advanced HER3-expressing solid malignancies.

• Hummingbird Bioscience Appoints Jan Møller Mikkelsen as Chairman of the Board

  11/29/2021

  Hummingbird Bioscience Holdings Limited, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, announced the appointment of Jan Møller Mikkelsen as Chairman of its Board of Directors.

• Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting

  11/10/2021

  Hummingbird Bioscience announced a Trials in Progress poster presentation outlining the Phase 1 clinical trial design for HMBD-002, a unique anti-VISTA antibody developed using Hummingbird's Rational Antibody Discovery platform to address VISTA-mediated suppression of anti-tumor immune responses, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer.

• Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer

  10/25/2021

  Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, announced it has entered into a clinical trial collaboration agreement with Merck.